Author

Liudmyla Arifova

Vanderbilt University

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Biophysics· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Approach:deep learning· 1 Research Focus:protein folding & dynamics· 1

Frequent Co-Authors

Di ZhuiD· 2 shared Douglas J. KojetiniD· 2 shared Mithun Nag Karadi GiridhariD· 2 shared Theodore M. KameneckaiD· 2 shared Xiaoyu YuiD· 2 shared Zane T. LaughliniD· 2 shared Ashish R. JhangianiiD· 1 shared Ashlyn G Winters· 1 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

Di ZhuORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Profiling the CFTR Variant Selectivity and Off-Target Interactions of VX-121

Ashish R. Jhangiani, John A. Olson, Austin Tedman, Catherine Foye, JaNise J Jackson, Ashlyn G Winters, J Renfrew White, Mia Perfetti, Grace M Abell, Crissey D. Cameron, Liudmyla Arifova, Brianna Corman, J. Paul Robinson, Charles P. Kuntz, Kaitlyn V. Ledwitch, , Jonathan P. Schlebach

This study evaluates VX-121's efficacy across 232 rare CFTR variants, finding it generally more effective than VX-445 but with one variant showing reduced selectivity.

bioRxiv · Jun 8, 2026 · PreprintPharmacology & Toxicology

Shifting the PPARγ conformational ensemble towards a transcriptionally repressive state improves covalent inhibitor efficacy

Liudmyla Arifova, Brian S. MacTavish, Zane T. Laughlin, Mithun Nag Karadi Giridhar, Jinsai Shang, Mei Li, Xiaoyu Yu, Di Zhu, Theodore M. Kamenecka, Douglas J. Kojetin

The paper investigates how covalent inhibitors of PPARγ shift its conformational state, affecting ligand binding and inhibitor efficacy.

eLife · Jan 21, 2026Peer-reviewedBiochemistry

Structural basis of PPARγ-mediated transcriptional repression by the covalent inverse agonist FX-909

Zane T. Laughlin, Liudmyla Arifova, Paola Munoz‐Tello, Xiaoyu Yu, Mithun Nag Karadi Giridhar, Jinhui Dong, Joel M. Harp, Di Zhu, Theodore M. Kamenecka, Douglas J. Kojetin

This study compares FX-909 to other covalent PPARγ inverse agonists, showing improved corepressor-selective inverse agonism and stabilization of a repressive conformation.

Journal of Medicinal Chemistry · Aug 13, 2025Peer-reviewedBiophysics